EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.

Christopher A Chapleau, Jane Lane, Lucas Pozzo-Miller, Alan K Percy

Current Clinical Pharmacology · 31.08.2013 · 8 (4) · 358-369

DOI: 10.2174/15748847113086660069 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Clinical Pharmacology, erschienen am 31.08.2013. Verfasst von Christopher A Chapleau und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, CIRC-320, The University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294-0021, USA. chris.a.chapleau@…. Hauptthemen laut MEDLINE: Drug Design. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodevelopmental disorders are a large family of conditions of genetic or environmental origin that are characterized by deficiencies in cognitive and behavioral functions. The therapeutic management of individuals with these disorders is typically complex and is limited to the treatment of specific symptoms that characterize each disorder. The neurodevelopmental disorder Rett syndrome (RTT) is the leading cause of severe intellectual disability in females. Mutations in the gene encoding the transcriptional regulator methyl-CpG-binding protein 2 (MECP2), located on the X chromosome, have been confirmed in more than 95% of individuals meeting diagnostic criteria for classical RTT. RTT is characterized by an uneventful early infancy followed by stagnation and regression of growth, motor, language, and social skills later in development. This review will discuss the genetics, pathology, and symptoms that distinguish RTT from other neurodevelopmental disorders associated with intellectual disability. Because great progress has been made in the basic and clinical science of RTT, the goal of this review is to provide a thorough assessment of current pharmacotherapeutic options to treat the symptoms associated with this disorder. Furthermore, we will highlight recent discoveries made with novel pharmacological interventions in experimental preclinical phases, and which have reversed pathological phenotypes in mouse and cell culture models of RTT and may result in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignAnimalsDisease Models, AnimalFemaleHumansMethyl-CpG-Binding Protein 2MiceMutationPhenotypeRett Syndrome

Substanzen

Methyl-CpG-Binding Protein 2

Autor:innen und Institutionen

  • Department of Pediatrics, CIRC-320, The University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294-0021, USA. chris.a.chapleau@gmail.com.

Förderung

  • NICHD NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Chapleau, C. A., Lane, J., Pozzo-Miller, L., & Percy, A. K. (2013). Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives. Current Clinical Pharmacology, 8(4), 358-369. https://doi.org/10.2174/15748847113086660069

Vancouver

Chapleau CA, Lane J, Pozzo-Miller L, Percy AK. Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives. Current Clinical Pharmacology. 2013;8(4):358-369. doi:10.2174/15748847113086660069

BibTeX
@article{Chapleau2013,
  author = {Chapleau, Christopher A and Lane, Jane and Pozzo-Miller, Lucas and Percy, Alan K},
  title = {Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives},
  journal = {Current Clinical Pharmacology},
  year = {2013},
  volume = {8},
  number = {4},
  pages = {358--369},
  doi = {10.2174/15748847113086660069}
}
Kostenlos starten →